Table of Contents
ISRN Obstetrics and Gynecology
Volume 2012 (2012), Article ID 245756, 11 pages
http://dx.doi.org/10.5402/2012/245756
Review Article

Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer

1Division of Gynecologic Oncology, “Angelo Nocivelli” Institute of Molecular Medicine, University of Brescia, 25123 Brescia, Italy
2Department of Clinical Pathology, Regional Center for Biomarkers, Azienda ULSS 12, 30122 Venice, Italy
3Department of Biomedical Sciences and Biotechnology, Medical Statistics Unit, University of Brescia, 25123 Brescia, Italy
4Istituto Oncologico Veneto IOV-IRCCS, 35128 Padova, Italy
5Department of Obstetrics and Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06511, USA

Received 20 February 2012; Accepted 3 April 2012

Academic Editors: E. Ginsburg and Y. S. Song

Copyright © 2012 Elisabetta Bandiera et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. J. Jacobs and U. Menon, “Progress and challenges in screening for early detection of ovarian cancer,” Molecular and Cellular Proteomics, vol. 3, no. 4, pp. 355–366, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. R. T. Greenlee, T. Murray, S. Bolden, and P. A. Wingo, “Cancer statistics, 2000,” Ca-A Cancer Journal for Clinicians, vol. 50, no. 1, pp. 7–33, 2000. View at Google Scholar · View at Scopus
  3. “FIGO (International Federation of Gynecology and Obstetrics) 26th Annual Report on the Results of Treatment in Gynecological Cancer,” International Journal of Gynecology & Obstetrics, vol. 95, supplement 1, pp. S1–S257, 2006.
  4. J. Folkman, K. Watson, D. Ingber, and D. Hanahan, “Induction of angiogenesis during the transition from hyperplasia to neoplasia,” Nature, vol. 339, no. 6219, pp. 58–61, 1989. View at Google Scholar · View at Scopus
  5. J. Folkman, “What is the evidence that tumors are angiogenesis dependent?” Journal of the National Cancer Institute, vol. 82, no. 1, pp. 4–6, 1990. View at Google Scholar · View at Scopus
  6. J. Folkman, “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nature Medicine, vol. 1, no. 1, pp. 27–31, 1995. View at Google Scholar · View at Scopus
  7. H. C. Hollingsworth, E. C. Kohn, S. M. Steinberg, M. L. Rothenberg, and M. J. Merino, “Tumor angiogenesis in advanced stage ovarian carcinoma,” American Journal of Pathology, vol. 147, no. 1, pp. 33–41, 1995. View at Google Scholar · View at Scopus
  8. G. Gasparini, E. Bonoldi, G. Viale et al., “Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas,” International Journal of Cancer, vol. 69, no. 3, pp. 205–211, 1996. View at Publisher · View at Google Scholar
  9. O. Abulafia, W. E. Triest, and D. M. Sherer, “Angiogenesis in primary and metastatic epithelial ovarian carcinoma,” American Journal of Obstetrics and Gynecology, vol. 177, no. 3, pp. 541–547, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. A. A. Alvarez, H. R. Krigman, R. S. Whitaker, R. K. Dodge, and G. C. Rodriguez, “The prognostic significance of angiogenesis in epithelial ovarian carcinoma,” Clinical Cancer Research, vol. 5, no. 3, pp. 587–591, 1999. View at Google Scholar · View at Scopus
  11. D. R. Senger, L. Van De Water, L. F. Brown et al., “Vascular permeability factor (VPF, VEGF) in tumor biology,” Cancer and Metastasis Reviews, vol. 12, no. 3-4, pp. 303–324, 1993. View at Google Scholar · View at Scopus
  12. M. Ueda, Y. Terai, K. Kumagai et al., “Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells,” Gynecologic Oncology, vol. 82, no. 1, pp. 162–166, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Ferrara, “Vascular endothelial growth factor,” European Journal of Cancer Part A, vol. 32, no. 14, pp. 2413–2422, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. R. A. Brekken and P. E. Thorpe, “Vascular endothelial growth factor and vascular targeting of solid tumors,” Anticancer Research, vol. 21, no. 6 B, pp. 4221–4229, 2001. View at Google Scholar · View at Scopus
  15. P. Salven, H. Mäenpää, A. Orpana, K. Alitalo, and H. Joensuu, “Serum vascular endothelial growth factor is often elevated in disseminated cancer,” Clinical Cancer Research, vol. 3, no. 5, pp. 647–651, 1997. View at Google Scholar · View at Scopus
  16. N. Ferrara and T. Davis-Smyth, “The biology of vascular endothelial growth factor,” Endocrine Reviews, vol. 18, no. 1, pp. 4–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. G. M. Abu-Jawdeh, J. D. Faix, J. Niloff et al., “Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms,” Laboratory Investigation, vol. 74, no. 6, pp. 1105–1115, 1996. View at Google Scholar · View at Scopus
  18. C. A. Boocock, D. S. Charnock-Jones, A. M. Sharkey et al., “Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma,” Journal of the National Cancer Institute, vol. 87, no. 7, pp. 506–516, 1995. View at Google Scholar · View at Scopus
  19. T. A. Olson, D. Mohanraj, L. F. Carson, and S. Ramakrishnan, “Vascular permeability factor gene expression in normal and neoplastic human ovaries,” Cancer Research, vol. 54, no. 1, pp. 276–280, 1994. View at Google Scholar · View at Scopus
  20. A. Kraft, K. Weindel, A. Ochs et al., “Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease,” Cancer, vol. 85, no. 1, pp. 178–187, 1999. View at Publisher · View at Google Scholar
  21. C. Tempfer, A. Obermair, L. Hefler, G. Haeusler, G. Gitsch, and C. Kainz, “Vascular endothelial growth factor serum concentrations in ovarian cancer,” Obstetrics and Gynecology, vol. 92, no. 3, pp. 360–363, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Gadducci, M. Ferdeghini, A. Fanucchi et al., “Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome,” Anticancer Research, vol. 19, no. 2 B, pp. 1401–1405, 1999. View at Google Scholar · View at Scopus
  23. C. A. Chen, W. F. Cheng, C. N. Lee et al., “Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival,” Gynecologic Oncology, vol. 74, no. 2, pp. 235–240, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. M. K. Oehler and H. Caffier, “Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer,” Anticancer Research, vol. 20, no. 6 D, pp. 5109–5112, 2000. View at Google Scholar · View at Scopus
  25. B. C. Cooper, J. M. Ritchie, C. L. W. Broghammer et al., “Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer,” Clinical Cancer Research, vol. 8, no. 10, pp. 3193–3197, 2002. View at Google Scholar · View at Scopus
  26. L. Li, L. Wang, W. Zhang et al., “Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer,” Anticancer Research, vol. 24, no. 3 B, pp. 1973–1979, 2004. View at Google Scholar · View at Scopus
  27. A. Harloziňska, P. Sedlaczek, J. Kulpa et al., “Vascular Endothelial Growth Factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma,” Anticancer Research, vol. 24, no. 2 C, pp. 1149–1157, 2004. View at Google Scholar · View at Scopus
  28. L. A. Hefler, R. Zeillinger, C. Grimm et al., “Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer,” Gynecologic Oncology, vol. 103, no. 2, pp. 512–517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Mahner, L. Woelber, C. Eulenburg et al., “TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients,” BMC Cancer, vol. 10, article no. 139, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Manenti, P. Paganoni, I. Floriani et al., “Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma,” European Journal of Cancer, vol. 39, no. 13, pp. 1948–1956, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. E. A. Boss, L. F. A. G. Massuger, C. M. G. Thomas, A. Geurts-Moespot, and H. Boonstra, “Vascular endothelial growth factor in ovarian cyst fluid,” Cancer, vol. 91, no. 2, pp. 371–377, 2001. View at Publisher · View at Google Scholar
  32. A. Bamias, V. Koutsoukou, E. Terpos et al., “Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy,” Gynecologic Oncology, vol. 108, no. 2, pp. 421–427, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Yamamoto, I. Konishi, M. Mandai et al., “Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels,” British Journal of Cancer, vol. 76, no. 9, pp. 1221–1227, 1997. View at Google Scholar · View at Scopus
  34. C. Rudlowski, A. K. Pickart, C. Fuhljahn et al., “Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 183–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Y. Dirix, P. B. Vermeulen, A. Pawinski et al., “Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients,” British Journal of Cancer, vol. 76, no. 2, pp. 238–243, 1997. View at Google Scholar · View at Scopus
  36. E. V. S. Høgdall, L. Christensen, S. K. Kjaer et al., “CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study,” Gynecologic Oncology, vol. 104, no. 3, pp. 508–515, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Markmann, B. Gerber, and V. Briese, “Prognostic value of Ca 125 levels during primary therapy,” Anticancer Research, vol. 27, no. 4 A, pp. 1837–1839, 2007. View at Google Scholar · View at Scopus
  38. J. A. Nagy, E. M. Masse, K. T. Herzberg et al., “Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation,” Cancer Research, vol. 55, no. 2, pp. 360–368, 1995. View at Google Scholar · View at Scopus
  39. A. D. Santin, P. L. Hermonat, A. Ravaggi, M. J. Cannon, S. Pecorelli, and G. P. Parham, “Secretion of vascular endothelial growth factor in ovarian cancer,” European Journal of Gynaecological Oncology, vol. 20, no. 3, pp. 177–181, 1999. View at Google Scholar · View at Scopus
  40. R. A. Burger, M. F. Brady, M. A. Bookman et al., “Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 28, no. 18, p. LBA1, 2010. View at Google Scholar
  41. T. Perren, A. M. Swart, J. Pfisterer et al., “ICON7: a phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer,” in Proceedings of the European Society for Medical Oncology Congress, ICON7 (ESMO '11), Milan, Italy, April 2011.